Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "TD"

1365 News Found

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Natco Q3FY22 PAT up 27% to Rs 80 Cr
News | February 19, 2022

Natco Q3FY22 PAT up 27% to Rs 80 Cr

The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.


AptarGroup reported 2021 sales at US $3.23 billion
News | February 18, 2022

AptarGroup reported 2021 sales at US $3.23 billion

AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.


Launches and margin sustainability hold key for Glenmark: ICICI Direct
News | February 15, 2022

Launches and margin sustainability hold key for Glenmark: ICICI Direct

Key takeaways of Q3FY22 quarter & conference call highlights


Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
News | February 14, 2022

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct

Key takeaways of recent quarter & conference call highlights


GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
News | February 08, 2022

GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22

EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Sun Pharma demonstrates strong performance on all fronts: ICICI Direct
News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses


Alembic receives USFDA tentative approval for fesoterodine fumarate
Drug Approval | February 02, 2022

Alembic receives USFDA tentative approval for fesoterodine fumarate

The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency


Alembic receives USFDA approval for clarithromycin tablets
Drug Approval | February 01, 2022

Alembic receives USFDA approval for clarithromycin tablets

Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA